| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5623419 | Alzheimer's & Dementia | 2008 | 9 Pages |
Abstract
In the absence of effective drugs for Alzheimer's disease (AD) and a validated roadmap or guideline for drug development, it is important to consider some of the limitations currently hampering AD drug development and some general principles for moving forward. This paper will address current barriers to developing drugs for AD, and offer new considerations for accelerating drug discovery, development, and clinical trials.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Lon S. Schneider,